Klaria Pharma Holding AB (publ.) (STO:KLAR)
0.6130
-0.0170 (-2.70%)
Sep 4, 2026, 5:24 PM CET
STO:KLAR Revenue
Klaria Pharma Holding AB (publ.) had revenue of 10.00K SEK in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 125.00K, down -98.88% year-over-year. In the year 2025, Klaria Pharma Holding AB (publ.) had annual revenue of 9.00M with 286.89% growth.
Revenue (ttm)
125.00K
Revenue Growth
-98.88%
P/S Ratio
1,358.41
Revenue / Employee
27.75K
Employees
4
Market Cap
150.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.00M | 6.67M | 286.89% |
| Dec 31, 2024 | 2.33M | 2.10M | 920.18% |
| Dec 31, 2023 | 228.00K | -6.31M | -96.51% |
| Dec 31, 2022 | 6.54M | -30.98M | -82.58% |
| Dec 31, 2021 | 37.52M | 29.52M | 369.16% |
| Dec 31, 2020 | 8.00M | -3.59M | -30.97% |
| Dec 31, 2019 | 11.59M | 10.76M | 1,309.37% |
| Dec 31, 2018 | 822.00K | -1.83M | -68.95% |
| Dec 31, 2017 | 2.65M | 2.29M | 639.39% |
| Dec 31, 2016 | 358.00K | 46.00K | 14.74% |
| Dec 31, 2015 | 312.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.93M |
| Cinclus Pharma Holding AB | 35.18M |
| Newbury Pharmaceuticals AB | 35.02M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 16.60M |
| Enorama Pharma AB | 3.26M |
Klaria Pharma Holding AB (publ.) News
- 4 days ago - Klaria Pharma Holding AB (publ.) Quarterly report: Q2 2026 - Filings
- 3 months ago - Klaria Pharma Holding AB (publ.) Quarterly report: Q1 2026 - Filings
- 6 months ago - Klaria Pharma Holding AB (publ.) Quarterly report: Q4 2025 - Filings
- 6 months ago - Klaria Pharma Holding AB (publ.) Annual report: Q4 2025 - Filings
- 9 months ago - Klaria Pharma Holding AB (publ.) Quarterly report: Q3 2025 - Filings